Cancer- and Chemotherapy-Induced Anemia

Abstract

Anemia is a common condition in patients with cancer, and its correction through either transfusion with packed red blood cells or the administration of erythropoiesis-stimulating agents (ESAs) is a supportive care measure. The purpose of the guidelines is to operationalize the evaluation and treatment of anemia in cancer patients and to enable patients and clinicians to evaluate treatment options in the context of risks and benefits. The updated guidelines include a number of important changes that respond to new FDA recommendations limiting the use of ESAs in cancer patients. Updates also include new tables on the risks and benefits of ESAs versus red blood cell transfusion and recommendations for administering parenteral iron products. For the most recent version of the guidelines, please visit NCCN.org